Pharsight

1. List of Pepaxto drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6992207	ONCOPEPTIDES AB	Melphalan derivatives and their use as cancer chemotherapeutic drugs	Jun, 2023 (2 months from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10543274	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10322182	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10869928	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)
US10285946	ONCOPEPTIDES AB	Lyophilized preparations of melphalan flufenamide	Apr, 2032 (9 years from now)
US11344622	ONCOPEPTIDES AB	Lyophilized preparation of cytotoxic dipeptides	Apr, 2032 (9 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 26, 2028
New Chemical Entity Exclusivity (NCE)	Feb 26, 2026

Drugs and Companies using MELPHALAN FLUFENAMIDE HYDROCHLORIDE ingredient

NCE-1 date: 2025-02-26

Market Authorisation Date: 26 February, 2021

Treatment: In combination with dexamethasone to treat relapsed or refactory multiple myeloma (refactory to at least 1 proteasome inhibitor, 1 immunomodulatory agent, and 1 anti-cd38 mab) in adults who received a...

Dosage: POWDER;INTRAVENOUS